Patheon was honored to collaborate with
the Tufts Center for the Study of Drug Development to quantify the time
and cost savings realized when partnering with a single-source CDMO, as
opposed to utilizing a multi-vendor approach. The study compared data
from five single-source contract manufacturing projects (three biologics
and two small molecule chemical entities) to benchmark results on
biopharmaceutical R&D costs and net returns for new
biopharmaceutical approvals.
Read the report from Tufts to learn the financial benefits of partnering with a single-source CDMO.
